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Abstract
Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph
+)
determine formation of different fusion genes that are associated with either Ph
+ acute lymphatic leukemia (Ph
+ ALL) or
chronic myeloid leukemia (CML). The ‘‘minor’’ breakpoint in Ph
+ ALL encodes p185
BCR/ABL from der22 and p96
ABL/BCR from
der9. The ‘‘major’’ breakpoint in CML encodes p210
BCR/ABL and p40
ABL/BCR. Herein, we investigated the leukemogenic
potential of the der9-associated p96
ABL/BCR and p40
ABL/BCR fusion proteins and their roles in the lineage commitment of
hematopoietic stem cells in comparison to BCR/ABL.
Methodology: All t(9;22) derived proteins were retrovirally expressed in murine hematopoietic stem cells (SL cells) and
human umbilical cord blood cells (UCBC). Stem cell potential was determined by replating efficiency, colony forming -
spleen and competitive repopulating assays. The leukemic potential of the ABL/BCR fusion proteins was assessed by in a
transduction/transplantation model. Effects on the lineage commitment and differentiation were investigated by culturing
the cells under conditions driving either myeloid or lymphoid commitment. Expression of key factors of the B-cell
differentiation and components of the preB-cell receptor were determined by qRT-PCR.
Principal Findings: Both p96
ABL/BCR and p40
ABL/BCR increased proliferation of early progenitors and the short term stem cell
capacity of SL-cells and exhibited own leukemogenic potential. Interestingly, BCR/ABL gave origin exclusively to a myeloid
phenotype independently from the culture conditions whereas p96
ABL/BCR and to a minor extent p40
ABL/BCR forced the B-cell
commitment of SL-cells and UCBC.
Conclusions/Significance: Our here presented data establish the reciprocal ABL/BCR fusion proteins as second oncogenes
encoded by the t(9;22) in addition to BCR/ABL and suggest that ABL/BCR contribute to the determination of the leukemic
phenotype through their influence on the lineage commitment.
Citation: Zheng X, Oancea C, Henschler R, Moore MAS, Ruthardt M (2009) Reciprocal t(9;22) ABL/BCR Fusion Proteins: Leukemogenic Potential and Effects on B
Cell Commitment. PLoS ONE 4(10): e7661. doi:10.1371/journal.pone.0007661
Editor: Catherine M. Verfaillie, KU Leuven, Belgium
Received July 7, 2009; Accepted October 7, 2009; Published October 30, 2009
Copyright:  2009 Zheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by grants from Deutsche Krebshilfe e.V. to Martin Ruthardt (107063) and to Reinhard Henschler (107068) in the joint project
‘Pathologische Genprodukte und ihre Wirkmechanismen’ (102362). Xiaomin Zheng was supported by a fellowship from German Jose Carreras Leukemia-
Foundation (DJCLS- F04/04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. M.R. is
further funded by grants from German Jose Carreras Leukemia-Foundation (DJCLS - R 07/27f), Deutsche Forschungsgemeinschaft (DFG-RU 728/3-1), Deutsche
Krebshilfe e.V. (DKH-107741), and Alfred und Angelika Gutermuth Foundation.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ruthardt@em.uni-frankfurt.de
Introduction
t(9;22)(q34;q11) is detected in 95% of chronic myeloid leukemia
(CML) cases as well as in 20–30% of adult acute lymphatic
leukemia (ALL) cases. CML is a myeloproliferative syndrome
characterized by an indolent chronic phase (CP) with an
overgrowing mature myeloid cell population, which is, if not
treated, inevitably followed by an acute phase, the so-called blast
crisis (BC). Clinically, BC resembles acute leukemia, with a poor
prognosis and resistance to therapy [1–3]. CML-BC displays a
myeloid phenotype in two-thirds of cases and a lymphatic
phenotype in the remaining one-third [1]. In contrast, Ph
+-ALL
is an acute disease from onset and is characterized by blasts that
are blocked, in the majority of cases, at the pre-lymphatic stage of
differentiation. Patients suffering from Ph
+ ALL constitute a high
risk group of ALL [4]. The factors that determine the evolution of
CML, as well as the biological differences between CML and Ph
+-
ALL, are almost completely unknown.
t(9;22) is usually a reciprocal translocation. A portion of
chromosome 9 fuses to chromosome 22 (der22), thereby replacing
a fragment ofchromosome 22, which inturn fuses to chromosome 9
(der9). The cytogenetic correlate of der22 is the so-called
Philadelphia chromosome (Ph). On chromosome 22, t(9;22)
involvesthebcr(breakpointcluster region) gene locus.Twoprincipal
breaks occur: the (major) M-bcr, between exons 12 and 16, and the
(minor) m-bcr, in the first intron of bcr. The breakpoint on
chromosome 9 is consistently located in intron 1 of the abl gene
locus. On der22, M-bcr leads to the creation of p210
BCR/ABL, which
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+ ALL-related p185
BCR/ABL
transcript is constant because the m-bcr breakpoint maps within an
intron [1]. Although m-BCR (p185
BCR/ABL-positive) is sporadically
found in CML, it is considered to be specific for Ph
+ ALL [5]. The
abl/bcr fusion genes on der9 mainly differ in the specific breakpoint
on chromosome 22. M-bcr results in the ‘‘small’’ abl/bcr, which
encodes a ‘‘small’’ ABL/BCR transcript that is detectable in 65% of
patients suffering from CML [6]. The resulting ABL/BCR fusion
protein has a theoretical molecular mass of 40 kDa - p40
ABL/BCR.
The fusion between m-bcr and abl leads to a ‘‘large’’ transcript,
which is present in 100% of examined patients with m-BCR Ph+
ALL [7]. This gene encodes a fusion protein with a theoretical
molecular mass of 96 kDa - p96
ABL/BCR.
The BCR/ABL fusion proteins are mutant ABL kinases. In
normal cells, ABL kinase activity is finely regulated in response to
growth factors and other stimuli. Through fusion to BCR, ABL
becomes constitutively activated. This leads to constitutive
activation of ‘‘down-stream’’ signal transduction pathways,
including Ras, Jak/Stat and PI-3 kinase [1,8]. The suppression
of constitutively active ABL kinase with specific kinase inhibitors,
such as Imatinib, Nilotinib [9] and Dasatinib [10], reverts the
oncogenic potential of BCR/ABL.
The ABL/BCR fusion proteins are BCR mutants [11]. It has
recently been reported that BCR is a negative regulator of
proliferation and oncogenic transformation [12]. It associates with
AF6 and Ras to form a trimeric complex, which is involved in the
down-regulation of Ras-mediated signaling at sites of cell-cell
contact to maintain cells in a non-proliferating state. The binding
site for AF6 is located at the C-terminus of BCR [12].
Furthermore, BCR inhibits Wnt signaling by blocking Tcf-1/b-
catenin-mediated transcription. It disrupts the Tcf-1/b-catenin
complex by direct binding to b-catenin and Tcf-1 [13]. Through
its Rho-GEF and Rac-GAP functions, BCR plays an important
role in cytoskeleton modeling by regulating the activity of Rho-like
GTPases, such as Rac, cdc42 and Rho [11,14].
Very little is known about the biology of p40
ABL/BCR and
p96
ABL/BCR and their roles in leukemogenesis. In both ABL/
BCRs, fundamental functional features of wt BCR, including
regulation of small Rho-like GTPases, are lost with negative
consequences on cell motility [11]. CML-associated p40
ABL/BCR
lacks the oncogenic DH/PH domains that are conserved in the
ALL-specific p96
ABL/BCR (Figure 1A). Thus, the ALL-specific
p96
ABL/BCR fusion protein is an N-terminally truncated Rho-GEF
and, therefore, a putative oncogene [15].
Herein, we investigated the leukemogenic potential of the ABL/
BCR proteins, as well as their influence on the lineage
commitment of early hematopoietic stem cells.
Results
The reciprocal t(9;22) fusion proteins p40
ABL/BCR and
p96
ABL/BCR are expressed in patient-derived Ph+ ALL and
CML cells
The fact that all m-BCR-positive Ph+ ALL and about two-
thirds of M-BCR-positive CML patients express the reciprocal
fusion transcript strongly suggests a fundamental role of the
reciprocal ABL/BCR fusion gene in induction of the leukemo-
genic phenotype. The modular organization of the translocation
partners and the resulting fusion proteins from m-BCR and M-
BCR in t(9;22), which are present in Ph
+ ALL and CML, is
presented in Figure 1A.
To confirm that the ABL/BCR transcript is translated into a
functional protein, we first investigated the expression of
p40
ABL/BCR and p96
ABL/BCR at the protein-level by Western
blotting of extracts obtained from patient-derived Ph+-ALL and
CML cells. We used SupB15, SD-1 and TOM-1 cells, as well as
samples from 3 Ph+ ALL patients, all known to present m-BCR
and expected to express the reciprocal p96
ABL/BCR. The CML-
blast crisis-derived BV173 and K562 cells and samples from 6
CML patients harboring the M-BCR, and thus expected to
Figure 1. The t(9;22) fusion proteins and their expression in Ph+ cells. (A) Modular organization of the translocation partners and the fusion
proteins in t(9;22). A schematic representation of the fusion proteins encoded by derivative 9 (der9) and 22 (der22), the Philadelphia chromosome, as
well as of their combination in m-BCR-positive Ph+ ALL and M-BCR-positive CML, respectively. CC - coiled coil oligomerization interface; Y177 -
Tyrosine phosphorylation site at aa 177; S/T kinase - serine/threonine kinase domain; DH - dbl homology domain; PH - pleckstrin homology domain;
GAP - Rac-GAP domain; STEV - PDZ-domain binding motif; SH2 and SH3 - Src homology domains 2 and 3; Y kinase - tyrosine kinase domain; AB - actin
binding domain. (B) Expression of the reciprocal ABL/BCR fusion proteins in Ph+ leukemia cell lines. Negative control: Phoenix cells; Tom-1, SD-1 and
SupB15 - cell lines derived from m-BCR-positive ALL patient samples; BV173 - cells derived from a sample obtained from a CML patient in lymphatic
BC; K562 - cells derived from a sample obtained from a CML patient in myeloid BC. (C) Expression of the reciprocal ABL/BCR fusion proteins in
samples from Ph+ leukemia patients. Negative controls - three samples from AML patients and one sample from a CML patient for p96
ABL/BCR in Ph+
ALL samples; one sample from an AML patient for p40
ABL/BCR in CML samples.
doi:10.1371/journal.pone.0007661.g001
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ABL/BCR, were also included. Samples
from patients with AML were used as negative controls. As shown
in Figure 1B, all Ph
+ ALL cell lines and 3/3 Ph
+ ALL patients
exhibited a band of about 96 kDa, which was absent in the CML-
derived cell lines and in the negative controls. In contrast, a band
of about 40 kDa was detected in only the lymphatic BV173 and in
3/6 CML patients. The myeloid K562 cells did not express the
p40
ABL/BCR (Figure 1B).
Taken together, these data show that the reciprocal ABL/BCR
proteins were expressed not only at the transcriptional level, but
also at the protein level in patient-derived cells. It is noteworthy
that, in contrast to CML, all tested m-BCR-positive Ph
+ ALL cells
expressed the reciprocal p96
ABL/BCR, suggesting a putative role for
this fusion protein in induction of the leukemic phenotype.
Both p40
ABL/BCR and p96
ABL/BCR, but not p185
BCR/ABL,
increase the replating efficiency of murine HSCs and
block their myeloid differentiation
Both CML and Ph
+ ALL have been proposed to originate from
a transformed stem cell. Therefore, we compared the effects of the
ABL/BCR fusion proteins and p185
BCR/ABL on the biology of
HSC. First, the in vitro replating efficiency in semi-solid medium in
the presence of hematopoietic growth factors of Sca1
+/lin
2 HSCs
transduced with p40
ABL/BCR,p 9 6
ABL/BCR or p185
BCR/ABL was
determined. c-catenin was used as a positive control [16]
(Figure 2A). Transgene expression was controlled in the colony
forming units (CFUs) from the first plating (Figure 2B). Here, we
show that the replating efficiency of the empty-vector transduced
controls was limited to one cycle of replating (Figure 2C). In
contrast, both p40
ABL/BCR and p96
ABL/BCR increased the replating
efficiency over four cycles, with a maintenance or increase in the
number of CFUs in each round of replating (Figure 2C). The
morphologies of the colonies were classified as type A, B or C
colonies according to the descriptions provided by Lavau and co-
workers[17,18]. As shownin Figure 2D, expressionofp96
ABL/BCR
led to type A colonies, which are typical compact colonies,
representing .90% of the p96
ABL/BCR-positive colonies. Also,
p40
ABL/BCR gave rise to more than 80% type A colonies. In
contrast, c-catenin CFU colonies were mainly of type B, with a
dense center surrounded by a halo of migrating cells, whereas
empty-vector controls and p185
BCR/ABL-positive cells exhibited
Figure 2. Effect of the t(9;22) fusion proteins on the biology of murine HSCs. (A) Experimental strategy for studying the influence of the
t(9;22) fusion proteins on the biology of murine HSCs. Sca1
+/lin
2 BM cells were infected with the indicated retroviruses and plated in semi-solid
medium supplemented with the indicated growth factors for determination of the serial replating potential. Cells from the first plating (I) round were
examined for the expression of differentiation-specific surface markers. Cells plated in liquid culture supplemented with the indicated growth factors
were used for cell cycle analysis and gene expression by qRT-PCR. (B) Sca1
+/lin
2 BM cells were infected with the indicated retroviruses and expression
levels of the transgenes were analyzed by Western blotting using the indicated antibodies. (C) Long-term serial replating. Sca1
+/lin
2 cells were
infected with the indicated retroviruses and plated into methyl-cellulose supplemented with the indicated growth factors to assess primary colony
formation. Colony numbers were counted on days 8–10. Cells were then harvested and serially replated. Colonies were counted on days 8–10 after
each replating. (D) Colony morphology during the first plating. Type A (compact colonies), type B (dense center surrounded by a halo of migrating
cells) and type C (diffuse colonies with mobile differentiating cells) colonies were distinguished. (E) Expression of differentiation-specific surface
markers. One representative experiment of three yielding similar results. (F) Sca1
+/lin
2 BM cells were infected with the indicated retroviruses and,
after 48 h, cell cycle progression was determined. The provided results are the average of three independent experiments +/2 SD. (G) Activation of
Wnt-signaling by the t(9;22) fusion proteins. BCR, p185
BCR/ABL, p40
ABL/BCR and p96
ABL/BCR and the Topflash and Fopflash reporter constructs were co-
transfected by electroporation into U937 cells. U937 cells expressing PML/RARa - positive control; pGL3basic - negative control. Luciferase activity
measured at 24 h post-transfection was normalized to Renilla luciferase activity. Each experiment was performed in triplicate a total of three times
with similar results. One representative experiment is given +/2 SD. (H) Sca1
+/lin
2 BM cells were infected with the indicated retroviruses and, at 48 h
post-infection, the expression levels of HoxB4, Cdkn1a (p21
(cip1/waf1)), c-Myc and SCL were analyzed by qRT-PCR. The relative concentration of each
mRNA was normalized to the concentration of the housekeeping gene GAPDH and is represented as 2
2D/D CT. Each experiment was performed in
triplicate a total of three times with similar results. One representative experiment is given +/2 SD.
doi:10.1371/journal.pone.0007661.g002
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differentiating cells (Figure 2D). The immature character of
p40
ABL/BCR-a n dp 9 6
ABL/BCR-positive CFU was confirmed by the
high expression levels of c-Kit and Sca1, and low levels of the
myeloid differentiation markers Gr-1 and Mac-1 in comparison to
p185
BCR/ABL-positive CFU and mock-transduced controls
(Figure 2E).
To study the influence of the t(9;22) fusion proteins on the cell
cycle progression of murine HSC, we maintained the transduced
cells in liquid culture for 48 h prior to cell cycle analysis
(Figure 2A). As shown in Figure 2F, expression of p185
BCR/ABL
did not lead to an increase in the percent of cells in S phase,
whereas expression of either p40
ABL/BCR or p96
ABL/BCR led to a
reduction in the percent of cells in G0/G1 phase with a
proportional increase in the amount of cells in the S phase, as
compared to the controls.
To explain these different effects on the biology of early HSC,
we investigated how the t(9;22) fusion proteins interfere with the
regulators of ‘‘stemness’’, such as Wnt-signaling, c-Myc, HoxB4,
Cdkn1a, Bmi-1 and SCL [19]. More specifically, we investigated
the effect of the ABL/BCRs on Wnt-signaling by measuring Tcf/
Lef transcriptional activity through determination Topflash/
Fopflash reporter activity in U937 cells expressing BCR,
p185
BCR/ABL, p40
ABL/BCR or p96
ABL/BCR. U937 cells expressing
PML/RARa, which is known to activate Wnt signaling, were used
as a positive control. In these cells, BCR, p185
BCR/ABL and
p40
ABL/BCR had no effect on Tcf/Lef-dependent transcription,
whereas p96
ABL/BCR activated Tcf/Lef-dependent transcription to
a larger extent than did PML/RARa (Figure 2G). Next, we
assessed the expression of HoxB4, Cdkn1a (p21
Cip1/Waf1), c-Myc
and SCL in Sca1
+/lin
2 HSCs expressing p185
BCR/ABL,
p40
ABL/BCR or p96
ABL/BCR by quantitative real time PCR (qRT-
PCR). Figure 2H shows that, in contrast to p185
BCR/ABL, both
p40
ABL/BCR and p96
ABL/BCR induced the transcription of HoxB4.
Conversely, p185
BCR/ABL, but not p40
ABL/BCR or 96
ABL/BCR, up-
regulated Cdkn1a expression. All of the fusion proteins down-
regulated c-Myc, whereas only p185
BCR/ABL and p40
ABL/BCR, but
not p96
ABL/BCR, down-regulated SCL expression. Bmi-1 was not
influenced by the t(9;22) fusion proteins (data not shown).
These findings indicate that all of the fusion proteins regulated
the expression of genes involved in the maintenance of stem cell
capacity; p185
BCR/ABL up-regulated Cdkn1a and down-regulated
c-Myc (Wilson et al. 2004), p40
ABL/BCR up-regulated HoxB4 and
down-regulated c-Myc and p96
ABL/BCR activated Wnt-signaling,
up-regulated HoxB4 and down-regulated c-Myc.
All t(9;22)-associated fusion proteins increased the
re-population potential of murine HSCs
To investigate whether and how p40
ABL/BCR, p96
ABL/BCR and
p185
BCR/ABL influence stem cell capacity, we performed a
competitive repopulating assay (CRA). CD45.1
+/Sca1
+/lin
2
HSCs transduced with p40
ABL/BCR, p96
ABL/BCR and p185
BCR/ABL
were inoculated together with CD45.2
+ HSCs into lethally
irradiated congenic CD45.2
+ recipient mice. Chimerism was
measured after 12 weeks in order to determine the re-population
capacity of these cells as an index of their stem cell capacity
(Figure 3A). Both ABL/BCR fusion proteins increased re-
Figure 3. Effect of the t(9;22) fusion proteins on the re-population capacity of murine HSC. (A) The schematic indicates the experimental
procedure for determination of the re-population potential of murine HSCs expressing t(9;22) fusion proteins. Sca1
+/lin
2 BM cells from CD45.1
+ mice
were infected with the indicated retroviruses and, at 48 h post-infection, the cells were transplanted together with CD45.2
+ BM cells into lethally (11
Gy) irradiated CD45.2
+ recipient mice. Analysis of donor chimerism was performed 12 weeks after transplantation. (B) Plots show representative
donor-derived chimerisms from individual mice at 12 weeks post-transplantation. (C) Graph of donor-derived chimerism in each mouse after long-
term reconstitution (4–5 mice/group).
doi:10.1371/journal.pone.0007661.g003
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ABL/BCR
(Figure 3B). Remarkably, p185
BCR/ABL also conferred increased
engraftment, although it did not increase serial replating efficiency,
as shown above. Finally, at short time points after transplantation,
the levels of chimerism in the peripheral blood were equivalent,
suggesting that the observed effects were unlikely to be a
consequence of differences in homing (data not shown).
Taken together, these data indicate that all t(9;22)-associated
fusion proteins are able to increase stem cell re-population of
Sca1
+/lin
2 HSCs.
Both p40
ABL/BCR and p96
ABL/BCR have leukemogenic
potential
The fact that the ABL/BCRs induce a leukemic phenotype in
HSC, which is characterized by a block of myeloid differentiation
and increased stem cell capacity similar to that of other leukemia-
associated fusion proteins [20], prompted us to investigate their
leukemogenic potential. Thus, Sca1
+/lin
2 murine HSCs trans-
duced with p40
ABL/BCR, p96
ABL/BCR and c-catenin (positive
control) were inoculated into sub-lethally (8 Gy) irradiated
recipients. As controls, we used recipients inoculated with
empty-vector transduced Sca1
+/lin
2 HSCs (Figure 4A). Mice
inoculated with control c-catenin-transduced cells became sick
within 16–245 days, whereas p40
ABL/BCR induced disease within
26–373 days after inoculation (Figure 4B). In contrast, mice
inoculated with p96
ABL/BCR-transduced cells showed a delay in the
onset of disease (241–412 days). Penetrance for all transgenes was
relevant (Figure 4B). The presence of both p40
ABL/BCR and
p96
ABL/BCR induced a myeloid leukemia-like phenotype with
maturation, associated with moderate splenomegaly (0.2–0.6 mg
spleen weight)[21](Figure 4C–E). The WBC in the leukemic mice
at diagnosis ranged from 15 to 34610
3 cells/mL (data not shown).
Taken together, these data show that both ABL/BCR fusion
proteins are able to induce a leukemic phenotype in vivo.
In contrast to p185
BCR/ABL, p96
ABL/BCR increases the serial
replating potential of early stem cell derived B-lymphatic
progenitors
p185
BCR/ABL and p96
ABL/BCR are constantly and exclusively co-
expressed in m-BCR-positive Ph
+ ALL, which exhibits an
immature phenotype blocked at an antigen-independent stage of
differentiation. This prompted us to compare the effects of the
ABL/BCR fusion proteins with those of p185
BCR/ABL on the
biology of HSC-derived B cell progenitors in vitro. Thus, the in
vitro replating efficiency in semi-solid medium in the presence of
SCF, Flt3 ligand (Flt3-L) and IL-7 of Sca1
+/lin
2 HSCs transduced
with p40
ABL/BCR, p96
ABL/BCR or p185
BCR/ABL was determined
(Figure 5A). Here, we show that the replating efficiency of the
empty-vector-transduced controls was limited to two cycles of
replating (Figure 5B). In contrast, p96
ABL/BCR increased the
replating efficiency by over five cycles and also led to an increased
number of CFUs. p40
ABL/BCR augmented the number of CFUs,
Figure 4. The leukemogenic potential of p40
ABL/BCR and p96
ABL/BCR. (A) Experimental strategy to model leukemia induced by the reciprocal
t(9;22) fusion proteins. Sca1
+/lin
2 BM cells were infected with the indicated retroviruses and inoculated into sub-lethally irradiated mice. As positive
and negative controls, we used c-catenin and empty vector-transduced cells, respectively. (B) Survival curves show the frequency of recipients
succumbing to disease after receiving the transduced cells. Statistical relevance was set at p,0.05. (C) May-Gru ¨nwald-Giemsa staining of cytospins
from BM and spleen of one representative mouse in each group. (D) Relative splenomegaly of p40
ABL/BCR-, p96
ABL/BCR-o rc-catenin-positive leukemia.
(E) Expression of differentiation-specific surface markers.
doi:10.1371/journal.pone.0007661.g004
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indicating an effect on proliferation (Figure 5B).
Both the p40
ABL/BCR- and p96
ABL/BCR-positive colonies exhib-
ited a lymphatic phenotype as revealed by strong positivity for the
B220 surface marker and absence of the Mac-1 marker for
myeloid cells (Figure 5C). In contrast, the p185
BCR/ABL-positive
colonies were nearly completely negative for B220 and exhibited a
myeloid phenotype as shown by positivity for Mac-1 (Figure 5C).
The morphology of the colonies was classified as type A, B or C
according to the myeloid CFUs described above. As shown in
Figure 5D, the expression of p40
ABL/BCR led to compact type A
colonies, whereas p96
ABL/BCR g a v er i s et ot y p eA( a b o u t4 0 % )a n d
smaller, less compact type B colonies (about 60%). Control cells
exhibited the type B morphology with mobile cells. In contrast,
p185
BCR/ABL-positive cells did not exhibit colonies in the second
plating round, but many viable cells were present that were
apparently unable to give rise to colonies (Figure 5D). The expression
of p40
ABL/BCR and p96
ABL/BCR induced a differentiation block as
revealed by the fact that the majority of the p40
ABL/BCR-a n d
p96
ABL/BCR-positive B220
+ B cell population expressed CD43, a
marker of the immature pro-B cell compartment. In contrast, most
p185
BCR/ABL-positive cells expressed the myeloid marker Mac-1, and
the few lymphatic B220
+ cells exhibited a more mature phenotype as
revealed by the absence of CD43 expression (Figure 5E).
Taken together, these data suggest that, upon receipt of
signaling that drives lymphatic commitment, p185
BCR/ABL exhibits
an apparently ‘‘paradox’’ phenotype characterized by expression
of the myeloid surface marker Mac-1, while p40
ABL/BCR increases
proliferation and p96
ABL/BCR fully transforms early B cell
progenitors.
BCR/ABL and p40
ABL/BCR block, but p96
ABL/BCR stimulates
the generation of CD19
+ B cell progenitors from human
CD34
+ UCBC
To exclude that the observed effects of the t(9;22) fusion proteins
on B cell commitment were specific to murine HSC, we studied the
effects of p185
BCR/ABL, p96
ABL/BCR and p40
ABL/BCR on the
generation of human B cell progenitors. Based on recent data
showing that both p185
BCR/ABL and p210
BCR/ABL block B cell
differentiation [22], we extended our experiments to the CML-
associated p210
BCR/ABL protein. To study early human B-
lymphopoiesis, we used a co-culture system with a monolayer of
the BM stroma cell line, MS-5, in which human CD34
+ umbilical
cord blood cells (UCBCs) differentiate to CD19
+ cells within 3–5
weeks. The addition of SCF and G-CSF highly enhances the
production of CD19
+ cells [23]. Therefore, CD34
+ UCBCs that
were retrovirally transduced with p185
BCR/ABL, p96
ABL/BCR or
p40
ABL/BCR were co-cultured with MS5 stroma cells in the presence
of SCFand G-CSF (Figure 6A). After threeweeks,the percentage of
CD19
+ cells was determined. Herein, we show that the amount of
CD19
+ cells derived from CD34
+ UCBCs expressing p40
ABL/BCR,
p185
BCR/ABL or p210
BCR/ABL was lower in comparison to that
derived from p96
ABL/BCR-expressing CD34
+ UCBCs (Figure 6B).
In summary, these findings support our data on the influence of
the t(9;22) fusion proteins on B cell commitment in the mouse.
Opposite effects of BCR/ABL and ABL/BCR on key factors
of lymphoid commitment and pre-B cell receptor
signaling
Our data suggest that BCR/ABL and ABL/BCR exert different
effects on the B cell commitment of early HSCs. Because ABL/
Figure 5. Differential effects of p40
ABL/BCR, p96
ABL/BCR and p185
BCR/ABL on the B cell commitment of murine HSCs. (A) Experimental
strategy for studying the influence of the reciprocal t(9;22) fusion proteins on the B cell commitment of murine HSCs. Sca1
+/lin
2 BM cells were
infected with the indicated retroviruses and plated in semi-solid medium supplemented with the indicated growth factors for determination of the
serial replating potential. Cells from the first plating (I) round and cells plated in liquid culture supplemented with the indicated growth factors were
examined for the expression of differentiation-specific surface markers. (B) Long-term serial replating. Sca1
+/lin
2 cells were infected with the
indicated retroviruses and plated into methyl-cellulose medium supplemented with the indicated growth factors to assess primary colony formation.
Colony numbers were counted on days 8–10. Cells were then harvested and serially replated. Colonies were counted on days 8–10 for each replating.
I-IV - number of the plating round. (C) Expression of differentiation-specific surface markers. (D) Colony morphology of the second plating. Type A
(compact colonies), type B (a dense center surrounded by a halo of migrating cells) and type C (diffuse colonies with mobile differentiating cells)
colonies were distinguished. p185
BCR/ABL exhibited a high number of viable cells that were not organized into colonies. (E) Determination of the
maturation stage of B220
+ lymphocytes by CD43 expression analysis. CD43 positivity is characteristic of immature pro-B cells.
doi:10.1371/journal.pone.0007661.g005
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proteins in leukemic cells, we studied the influence of their co-
expression with BCR/ABL on the biology of HSC-derived B cell
progenitors in vitro. We retrovirally expressed p185
BCR/ABL,
p210
BCR/ABL, p40
ABL/BCR and p96
ABL/BCR and the combinations
of p185
BCR/ABL/p40
ABL/BCR and p185
BCR/ABL/p96
ABL/BCR in
Sca1
+/lin
2 HSCs. These cells were plated either in semi-solid
medium for the determination of their serial replating potential or
in liquid culture for detection of the expression of key regulators of
B cell differentiation; in both cases, the cells were cultured in the
presence of SCF, Flt3-L and IL-7 as described in Figure 7A. The
expression levels of the single transgenes did not differ between the
cells that expressed the transgenes alone or in combination,
suggesting that the observed effects were unlikely to be a
consequence of differences in expression (Figure 7B). As shown
in Figure 7C, neither p185
BCR/ABL nor p210
BCR/ABL increased the
Figure 6. Differential effects of p40
ABL/BCR, p96
ABL/BCR, p185
BCR/ABL and p210
BCR/ABL on the B cell commitment of human HSC. (A)
Experimental strategy for studying the influence of the reciprocal t(9;22) fusion proteins on the B cell commitment of human CD34
+ UCBCs. CD34
+
UCBCs were infected with the indicated retroviruses and plated on MS5 cells in the presence of SCF and G-CSF. After three weeks, the percentage of
CD19
+ cells was determined. (B) Histograms representing CD19
+ cells in the GFP-positive cell population. The experiments were performed twice
with similar results.
doi:10.1371/journal.pone.0007661.g006
Figure 7. Influence of the t(9;22) fusion proteins alone or in combination on B cell commitment and expression of B cell-specific
gene transcripts. (A) Experimental strategy for studying the influence of the reciprocal t(9;22) fusion proteins on the B cell commitment of murine
HSCs. Sca1
+/lin
2 BM cells were infected with the indicated retroviruses and plated in semi-solid medium supplemented with the indicated growth
factors for determination of the serial replating potential. (B) Transgene expression in transduced Sca1
+/lin
2 BM cells as determined by Western
blotting using the indicated antibodies. (C) Long-term serial replating of Sca1
+/lin
2 cells infected with the indicated retroviruses and plated into wells
containing methyl-cellulose medium supplemented with the indicated growth factors to assess primary colony formation. Colony numbers were
determined on days 8–10. Cells were harvested and replated for the determination of the serial replating potential (D–E). Influence of the t(9;22)
fusion proteins on key factors involved in B cell commitment and the pre-B cell receptor complex. Sca1
+/lin
2 BM cells were infected with the
indicated retroviruses and, at 48 h post-infection, the expression of PAX5, E2A, ID2, BLNK, CD19 and CD79a were analyzed by qRT-PCR. The relative
concentration of each mRNA was normalized to the concentration of the housekeeping gene GAPDH and is represented as 2
2D/D CT. Each
experiment was performed in triplicate a total of three times with similar results. One representative experiment is given +/2 SD.
doi:10.1371/journal.pone.0007661.g007
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empty vector-transduced controls. Co-expression of p40
ABL/BCR
and p185
BCR/ABL led to an increase in the CFU, indicating an
effect on proliferation, whereas p96
ABL/BCR together with
p185
BCR/ABL not only increased the CFU-number, but also the
replating efficiency as compared to p40
ABL/BCR and p96
ABL/BCR
alone. Taken together, these data suggest that the reciprocal
t(9;22) fusion proteins cooperate in the determination of a
leukemic phenotype for B cell progenitors.
The different phenotypic effects of p40
ABL/BCR and p96
ABL/BCR
and the apparent ‘‘paradox’’ effect of p185
BCR/ABL on B cell
development prompted us to investigate the influence of the t(9;22)
fusion proteins on fundamental steps of B cell development:
commitment and pre-B cell differentiation. Here, we studied the
influence of the t(9;22) fusion proteins on E2A and PAX5, which
are both indispensable for the commitment of stem cells to the B
cell lineage [24,25]. Their expression was determined by qRT-
PCR in Sca1
+/lin
2 HSCs expressing p185
BCR/ABL, p210
BCR/ABL,
p40
ABL/BCR or p96
ABL/BCR, as well as those co-expressing
p185
BCR/ABL and p40
ABL/BCR or p185
BCR/ABL and p96
ABL/BCR.
As shown in Figure 7D, both BCR/ABL fusion proteins abolished
the expression of PAX5 and strongly reduced that of E2A, in
contrast to p40
ABL/BCR and p96
ABL/BCR, neither of which strongly
impacted the expression of E2A or PAX5 alone. In cells co-
expressing p185
BCR/ABL, p40
ABL/BCR almost completely reverted
the abolition of PAX5, but not of E2A expression. Conversely,
p96
ABL/BCR only partially reverted the PAX5 suppression and
nearly completely reverted the down-regulation of E2A. To
understand how BCR/ABL regulates the expression of PAX5 and
E2A, we determined the expression level of the transcription
suppressor ID2, which is known to regulate both PAX5 and E2A
[26,27]. We found that both p185
BCR/ABL and p210
BCR/ABL up-
regulated ID2, an effect that was nearly completely abolished by
the ABL/BCRs, which did not have any effect on ID2 expression
when expressed independently (Figure 7D).
The targeted disruption of structural components or down-
stream signaling proteins of the pre-B cell-receptor complex results
in the arrest of B cell development. Importantly, the expression
and activity of proteins that are critical for pre-B cell receptor
signaling are strictly regulated [28]. Therefore, we addressed the
question of whether t(9;22) fusion proteins interfere with the
expression of key components of the proximal pre-B cell signaling
cascade, such as the adaptor protein BLNK (or SLP65)[29], the
co-receptor CD19 and the signaling chain Iga (CD79a). As shown
in Figure 7E, the BCR/ABLs abolished the expression of BLNK
and CD79a and reduced that of CD19. The CML-associated
p40
ABL/BCR, in contrast to p96
ABL/BCR, also reduced the expression
of BLNK and CD79a, whereas neither of these proteins influenced
the expression of CD19. It is noteworthy that both reverted, at
least partially, the effects of p185
BCR/ABL on the pre-B cell receptor
complex components.
Taken together, these data strongly suggest that the BCR/ABL
fusion proteins inhibit signaling pathways that are indispensable
for normal B cell development at an early stem cell stage, an effect
that is partially reverted by the reciprocal ABL/BCR fusion
proteins.
Discussion
Until now, the biology of Ph+ leukemia has been strictly limited
to der22-encoded BCR/ABL and the related signal transduction
pathways. Only CML-CP, a myeloproliferative syndrome, can be
explained by the biology of BCR/ABL alone. It seems that
p210
BCR/ABL is able to induce and maintain indolent CML-CP. In
fact, mathematical analysis together with studies on murine
embryonic stem cells strongly suggests that BCR/ABL alone is
sufficient to induce CML-CP without the need for any additional
mutations [30,31]. Progression to acute blast crisis is associated
with additional mutations that might be independent of reciprocal
ABL/BCR fusion protein expression, as suggested by the fact that
p40
ABL/BCR is not uniformly present in CML. In contrast, it is
unlikely that an acute leukemia such as Ph+ALL is induced and
maintained by only one mutation. The fact that p96
ABL/BCR is
uniformly expressed in Ph+ALL strongly suggests an important
role for this fusion protein in the initiation and maintenance of
Ph+ ALL.
Herein, we provide the first evidence that t(9;22) does not give
rise only to one, but to two leukemogenic fusion proteins, the
BCR/ABL and ABL/BCR fusion proteins. Both ABL/BCR
fusion proteins are able to induce a leukemic phenotype in vitro,a s
characterized by a block of differentiation and, in the case of
p96
ABL/BCR, of an increased replating efficiency of primitive HSCs
under conditions that permit myeloid commitment. In contrast,
as already reported for p210
BCR/ABL [32], p185
BCR/ABL was not
able to block differentiation of myeloid precursors or increase
replating efficiency. The lack of increased replating efficiency
can be explained by the fact that, in contrast to p40
ABL/BCR and
p96
ABL/BCR, p185
BCR/ABL up-regulated Cdkn1a expression and did
not up-regulate Wnt-signaling or HoxB4 expression. The up-
regulation of Cdkn1a together with the down-regulation of c-Myc
likely contributes to the maintenance of stem cell capacity by
p185
BCR/ABL. These findings suggest that the influence of
p185
BCR/ABL on primitive HSCs is characterized by the induction
of a ‘‘dormant’’ or ‘‘silent’’ state, whereas p40
ABL/BCR- and
p96
ABL/BCR induce proliferation of HSCs. Hence, we hypothesize
that the t(9;22) fusion proteins are active at different levels of the
stem cell hierarchy [33].
Interestingly, p40
ABL/BCR and p96
ABL/BCR increased not only the
stem cell capacity of primitive HSCs, but also exhibited
leukemogenic potential, as shown in the transduction/transplan-
tation model. The long latency, especially of p96
ABL/BCR-positive
leukemia, may be attributed to the need for additional mutations.
Previous data indicated that N-terminally truncated Rho-GEFs,
such as NET1, may have oncogenic potential, mainly due to the
presence of the Rho-GEF domain, which is defined by the DH-
and PH-domains [15,34]. Notwithstanding the differences be-
tween p40
ABL/BCR and p96
ABL/BCR regarding the presence of the
putative oncogenic DH/PH domain, we have shown that both
ABL/BCRs behave as hematopoietic oncogenes capable of
inducing a leukemic phenotype in vivo. From our data, p96
ABL/BCR
seems to be the stronger oncogene as compared to p40
ABL/BCR
because of its capacity to increase the replating efficiency and stem
cell capacity of primitive HSC. This characteristic might account
for the aggressive biological behavior of Ph
+ ALL compared to the
initially indolent CP-CML.
The fact that p40
ABL/BCR exhibits oncogenic potential may be
attributed to its ability, which is shared by p96
ABL/BCR, to activate
Rac, a key player in the leukemogenesis of Ph+ leukemia.
Furthermore, both ABL/BCRs inhibit Rho activation, which may
contribute to the increase in stem cell capacity [11].
The activation of Rac is a common theme for ABL/BCR and
BCR/ABL. This attribute may be the basis for the clinical
relevance of the reciprocal t(9;22) fusion proteins, as they could
maintain key signaling pathways, such as Rac signaling, upon
effective inhibition of BCR/ABL kinase activity. In this way, the
ABL/BCRs could play an important role in the grade of response
to kinase inhibitors that target BCR/ABL. The capacity of ABL/
BCR to autonomously induce leukemia suggests that the presence
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ABL/BCR or p96
ABL/BCR contributes to the maintenance of a
leukemic subpopulation upon inhibition of BCR/ABL by ATP-
analogues such as Imatinib, Dasatinib or Nilotinib, a scenario of
particular importance in Ph+ ALL. One could speculate that the
presence of ABL/BCR supports the proliferation of cells
harboring BCR/ABL mutants with lower kinase activity, such as
the T315I, which boasts nearly complete resistance to small
molecules [35–36].
The clinical significance of p40
ABL/BCR was addressed in
s e v e r a lc l i n i c a ls t u d i e st h a tinvestigated the impact of the
presence of der9 on clinical outcome; its significance is still
controversially discussed [37–39]. A recent study on CML
patients revealed that deletions of der9 spanning the ABL/BCR
breakpoint, and thus abrogating the expression of p40
ABL/BCR,
were associated with an adverse prognosis [40]. Based on our
data, one could speculate that these patients lacked the pro-
proliferative effects of p40
ABL/BCR at the stem cell level with a
higher proportion of quiescent stem cells due to the up-regulation
of Cdkn1a by BCR/ABL in HSCs [8].
In contrast to the BCR/ABLs, p40
ABL/BCR and p96
ABL/BCR
allow for myeloid and lymphatic commitment of murine HSCs.
These data are confirmed by our findings on the B cell
development of human UCBCs with the exception of p40
ABL/BCR
blocks it like BCR/ABL. These different effects of p40
ABL/BCR on
murine and human HSC may be due to differences between
UCBCs and murine HSCs regarding their ‘‘maturation’’ state.
Based on our data presented here, p185
BCR/ABL and p210
BCR/
ABL do not allow the commitment of HSCs to the lymphoid lineage
because, in stem cell-derived B cell progenitors, both of these
proteins down-regulate PAX5 and E2A. Expression of both PAX5
and E2A is essential for B cell lineage commitment. The critical
contribution of PAX5 to lineage selection is illustrated by loss-of-
function studies. In its absence, pro-B cells assume a multipotential
phenotype and differentiate (under appropriate growth factor
conditions) to T cells, NK cells, dendritic cells, macrophages,
neutrophils or erythroid precursors. Conditional PAX5 deletion
results in the retrodifferentiation of B cells to an uncommitted
progenitor cell stage [24]. In addition, E2A expression is essential
for B cell lineage commitment. Similar to B cell progenitors that
lack Pax5, E2A-deficient cells reconstitute T cell, natural killer cell,
myeloid, dendritic and erythroid lineages, but not B cells,
following transfer into lethally irradiated mice. Interestingly,
similar to the reported multipotency of B cell progenitors that
lack Pax5, E2A-deficient cells possess stem-cell-like properties,
including the expression of genes that are normally associated with
non-B cell lineages [25]. Therefore, the ‘‘paradox’’ behavior of
p185
BCR/ABL-expressing HSCs upon mIL-7, mSCF, and Flt3-L
influence, which is indicated by the expression of myeloid surface
markers, may produce a scenario similar to a PAX5 or E2A
deletion with a blockage of B cell commitment. The mechanism by
which BCR/ABL down-regulates PAX5 and E2A is most likely
related to up-regulation of ID2. ID2 likely has other effects in
addition to its ability to down-regulate PAX5. It is known that the
DNA-binding activity of PAX5 is decreased in ID2-overexpressing
B cells and enhanced in ID2
2/2 B cells [26].
BCR/ABL not only inhibits key factors involved in B cell
commitment, but also interferes with pre-B cell receptor signaling
by down-regulating key proteins whose deregulation causes a block
of differentiation at an early pre-B or pro-B cell level. This was
confirmed by recent findings that indirectly showed an effect of
BCR/ABL on pre-B cell receptor signaling. More specifically, it
was shown that, in Ph
+ ALL cell lines, expression of the main pre-
B cell receptor signaling components was restored upon exposure
to Imatinib [41].
The negative influence of BCR/ABL on B cell commitment
strongly suggests that, for the determination of the Ph
+ ALL
phenotype, an additional mechanism that allows t(9;22)-positive
precursors to engage in B cell commitment, or at least to maintain
B cell characteristics, must be present. Together with the fact that
100% of M-BCR Ph
+ALL cells expressed the reciprocal ABL/
BCR fusion proteins, our observation that the ABL/BCRs at least
partially reversed the effects of BCR/ABL on B cell commitment
indicates that they are the first candidates for this role. This result
is in apparent contradiction with the transgenic mouse models of
BCR/ABL-positive ALL [42,43]. In both models, additional
mutations that substitute for the role of ABL/BCR can not be
excluded. In fact, the expression of BCR/ABL alone was shown to
mainly induce a CML-like disease in mice [44].
Taken together, we show for the first time that t(9;22) gives rise
to two fusion proteins with leukemogenic potential, BCR/ABL
and ABL/BCR, and our data provide the first evidence that, in m-
BCR-positive ALL, p96
ABL/BCR cooperates with p185
BCR/ABL in
the determination of the leukemic phenotype.
Materials and Methods
Plasmids
All cDNAs encoding p185
BCR/ABL, p210
BCR/ABL, p40
ABL/BCR
and p96
ABL/BCR were described previously [11,38]. All retroviral
expression vectors used in this study were based on the bi-cistronic
vectors PINCO or PAULO, with or without an internal ribosomal
entry site (IRES) to drive translation of the two transgenes.
PINCO and PAULO were converted into GatewayH-destination
vectors by the introduction of a GatewayH cassette according to
the manufacturer’s instructions (Invitrogen, Karlsruhe, Germany).
All related inserts were available in the GatewayH entry-vector
(pENTR1A) for recombination into the destination vectors by
using the ‘‘LR-clonase’’ enzyme kit (Invitrogen) [38].
Cell Lines, Cell Culture, Transfection and Western Blotting
All cell lines were obtained by the German Collection of
Microorganisms and Cell Cultures (DSMZ). BV173, SD-1 and
U937 cells were maintained in RPMI 1640 supplemented with
10% FCS (Invitrogen). TOM-1 cells were maintained in Iscove’s
Medium supplemented with 10% FCS and SupB15 in RPMI 1640
supplemented with 15% FCS. U937 cells were transduced with
transgenes by electroporation using the Nucleofection technology
according to the manufacturer’s instructions (Amaxa, Heidelberg,
Germany). The ecotropic Phoenix packaging cells were cultured in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen) supple-
mented with 10% FCS and were transfected by the calcium-
phosphate precipitation method according to widely established
protocols.
Western blot analyses were performed according to widely
established protocols. The following antibodies were used: anti-
ABL (a-ABL) (St. Cruz Biotechnology, Santa Cruz, CA, USA) and
anti-BCR (a-BCR)(St. Cruz Biotechnology). Blocking and anti-
body incubation were performed in 5% low-fat dry milk, followed
by washing in Tris-buffered saline (TBS) (10 mM Tris-HCl pH 8,
150 mM NaCl) containing 0.1% Tween20 (TBS-T).
Topflash/Fopflash transactivation
The reporter constructs pRT-LK, pGL3-OT and pGL3-OF
were electroporated by nucleofection into U937 cells together with
isomolar quantities of the pCDNA3 expression vector encoding
the transgenes of interest. After 24–36 h, luciferase activity was
determined using the Dual-Luciferase Reporter Assay System
according to the manufacturer’s instructions (Promega, Man-
The ABL/BCR Fusion Proteins
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7661nheim, Germany). Luciferase activity was normalized using a co-
transfected construct that encodes Renilla luciferase under the
control of a PGK-promoter. Results are given as the ratio between
Topflash and Fopflash luciferase activity.
Patient samples and umbilical cord blood cells (UCBC)
Samples of mononuclear BM cells were obtained from patients
with CML blast crisis or Ph+ ALL at first diagnosis and were
frozen after informed and written consent with the approval of the
ethics committee of the Goethe-University of Frankfurt. Immedi-
ately after thawing, the cells were lysed in Laemmli buffer and
submitted to Western blot analysis.consecutive transduction
rounds, every 8 to 12 hours, were done. Human umbilical cord
blood was kindly provided by the Cord Blood Bank subdivision of
the New York Blood Bank from healthy full-term pregnancies with
the approval of the institutional review board. Human CD34+
cells were selected and CD34
+ UCBC were enriched by
immunomagnetic selection as described previously [45] and pre-
stimulated for 48 hours in Quality Biological serum-free (QBSF)-
60 medium (Quality Biological, Gaithersburg, MD) supplemented
with c-Kit ligand (100 ng/ml; Kirin, Gunma, Japan), Flt3 ligand
(100 ng/lL; Imclone Systems, New York, NY) and thrombopoietin
(100 ng/ml; Kirin) prior to use.
Isolation of Sca1
+/lin
2 HSCs
Sca1
+/lin
2 HSCs were isolated from 8 to 12-week-old female
C57BL/6N mice (Harlan Winkelmann GmbH, Borchen Ger-
many) after euthanization by CO2-asphyxiation. BM was
harvested from the femura and tibiae by flushing the bones with
a syringe and 26-gauge needle. The cells were ‘‘lineage depleted’’
by labeling the cells with biotin-conjugated lineage panel
antibodies against B220, CD3e, Gr-1, Mac-1 and Ter-119 (BD/
Pharmingen, San Diego, CA). Labeled cells were removed using
streptavidin loaded ‘‘MACS’’ cell separation columns. Sca1
+ cells
were purified by immunomagnetic beads using the ‘‘MACS’’ cell
separation columns according to the manufacturer’s instructions
(Myltenyi, Bergisch-Gladbach, Germany). Prior to further use, the
purified cells were pre-stimulated for 2 days in medium containing
either mIL-3 (20 ng/mL), mIL-6 (20 ng/mL) and mSCF (100 ng/
mL) (Cell Concepts, Umkirch, Germany) for myeloid commitment
or mIL-7 (20 ng/mL), Flt3-L (20 ng/mL) and mSCF (100 ng/
mL) for lymphatic commitment.
Retroviral infection
Ecotropic Phoenix packaging cells were transfected with
retroviral vectors as described before. Retroviral supernatant was
collected at days 2 and 3 after transfection. Target cells were
plated onto retronectin-coated (Takara-Shuzo, Shiga, Japan) non-
tissue culture-treated 24-well-plates and exposed to the retroviral
supernatant for 3 hours at 37uC in the presence of 4 mg/mL
polybrene (Sigma, Steinheim, Germany). Cells were centrifuged at
2.200 rpm for 45 min. The infection was repeated 4 times and the
minimal accepted infection efficiency was 70%, as assessed by the
detection of GFP positive cells by Fluorescence-Activated Cell
Sorting (FACS). Differences in the infection efficiency between
samples did not exceed 10%.
For the retroviral transduction of human UCBC, vesicular
stomatitis virus glycoprotein (VSV-G)-pseudotyped retrovirus was
generated by transiently transfecting H29 cells with 10 ug of
vector DNA by calcium phosphate precipitation. After 72 hours,
the H29 supernatant was used for cross-transduction of PG13
packaging cells in the presence of polybrene (8 ug/mL; Sigma, St.
Louis, MO). High-titer retrovirus-producing PG13 subclones were
selected by cell sorting for high EGFP expression. Retrovirus-
containing supernatants were harvested from PG13 clones
incubated in QBSF for 8 to 12 h, supplemented with 100 ng/ml
of c-Kit ligand, Flt3 ligand, thrombopoietin and 4 ug/ml
polybrene, filtered through a 0.45-Am filter (Costar, Acton,
MA), and applied immediately to the CD34
+ cells on retro-
nectin-coated six-well plates (Takara). Three consecutive rounds of
transduction were performed.
Cell cycle analysis
Sca1
+/lin
2 cells were collected from the cultures at 2 days post-
infection, washed in PBS and fixed with 70% ethanol at 220uC.
The cells were re-suspended in PBS containing propidium iodide
(PI)(50 ug/ml) and RNAse (5 ug/ml) (Sigma, Steinheim, Ger-
many) and incubated at 37uC for 30 min. The cells were
immediately evaluated by FACS.
Colony assays for determination of the colony forming
cell (CFC) number and replating efficiency
At day 5 post-infection, Sca1
+/lin
2 cells were plated at
5610
3 cells/mL in methyl-cellulose supplemented with either
mIL-3 (20 ng/mL), mIL-6 (20 ng/mL) and mSCF (100 ng/mL)
for myeloid commitment or mIL-7 (20 ng/mL), Flt3-L (20 ng/
mL) and mSCF (100 ng/mL) for lymphatic commitment (Stem-
Cell Technologies, Vancouver, Canada). On day 10 after plating,
the number of colony forming units (CFU) was determined. After
washing out from the methyl-cellulose, the cells were stained with
specific antibodies for the detection of surface marker expression
by FACS. 5610
3 cells/plate were replated in methyl-cellulose,
thus permitting determination of the serial replating potency.
Differentiation was assessed by the expression of c-Kit, Sca1, Gr-1
and Mac-1 (BD/Pharmingen) by FACS.
Competitive re-population assay (CRA)
All animals studies were conducted in accordance with national
animal protection laws and were approved by the Institutional
Review Board (Regierungspra ¨sidium Darmstadt - F 39/06). The
CRA was based on the CD45.1 - CD45.2 chimerism of C57BL/
6N mice as described previously (Bug et al., 2004). Two days after
retroviral infection, 10
4 CD45.1
+/Sca1
+/lin
2 cells were injected
into lethally (11 Gy) irradiated CD45.2
+ female recipients together
with 5610
4 normal Ly5.2
+ BM cells. The portion of CD45.1
+
donor cell-derived hematopoietic cells was determined by FACS
analysis of cells after 12 weeks on BM – MNC. The cells were
stained with conjugated monoclonal antibodies specific for
CD45.1 and CD45.2 or with the mouse IgG2a isotype control
(BD/Pharmingen).
Transduction/transplantation model of leukemia
Female C57BL/6N mice that were 8–12 weeks of age (Harlan
Winckelmann, Borchen, Germany) were used as recipients and
donors. Sca1
+/lin
2 were isolated as described above. Recipients
were sub-lethally irradiated with 8.5 Gy. 5610
4 transduced Sca1
+/
lin
2 were inoculated into anesthetized mice by retro-orbital
injection. The mice were sacrificed at the first appearance of
morbidity, loss of weight (.10%), neurological abnormalities,
failure to thrive or diarrhea. Statistical relevance was determined
by the Log-rank test. The isolation of BM cells was performed as
described above. Spleen cells were isolated by passing the tissue
through a 40 mM Nylon cell strainer (Beckton-Dickinson, Le Pont
de Claix, France). Whole BM and spleen cells were then cytospun
on glass slides and stained withMay-Gru ¨nwald-Giemsa. For surface
marker analysis, the MNC were enriched on a Ficoll density
gradient. Statistical relevance was determined by the Log-rank test.
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For B cell induction, 2610
4 transduced CD34
+ cells were plated
on MS-5 cells in MEM alpha supplemented with 10% FCS,
0.1 mM monothiolglycerol, 2 mM glutamine, 10 ng/ml huSCF
and 5 ng/ml huG-CSF and were demi-depopulated on a weekly
basis [23]. After three weeks, the suspension cells were harvested
for further analysis.
Quantitative real time PCR (qRT-PCR) – Taqman
TM
Total RNA and first strand cDNA were obtained from Sca1
+/
lin
2 HSCs according to standard protocols. The TaqMan
TM PCR
was conducted in duplicate following standard protocols using the
ABI PRISM 7700 (Applied Biosystems, Darmstadt, Germany).
For the quantification of mRNA, gene expression quantification
using ‘‘Assay-on-demand’’ for Cdkn1a, HoxB4, c-Myc, SCL,
PAX5, E2A, ID2, BLNK, CD79 and D19 was performed
according to the manufacturer’s instructions (Applied Biosystems).
Normalization to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was done for each sample. CT values were exported
into a Microsoft Excel worksheet for calculation of fold changes
according to the Comparative CT method. The amount of target,
normalized to endogenous GAPDH, is given by 2
2D/D CT.
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